Clinical Trial

MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 28, 2025 (before its estimated August 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
This anchored matching-adjusted indirect comparison (MAIC) evaluates the relative efficacy of fruquintinib-paclitaxel (using IPD from the FRUTIGA trial, n=703) versus ramucirumab-paclitaxel (using published AgD from RAINBOW-Asia, n=440) in advanced gastric/GEJ adenocarcinoma. Baseline characteristics are adjusted via entropy balancing weights. Primary endpoint is progression-free survival (PFS) analyzed by Bucher method; secondary endpoints include overall survival (OS) and objective response rate (ORR). Sensitivity analyses comprise restricted mean survival time (RMST) analysis and simulated treatment comparison (STC).
Trial Details
NCT Number NCT07144995
Lead Sponsor Sun Yat-sen University
Conditions Advanced Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Fruquintinib, Ramucirumab
Enrollment 1,143 participants
Start Date 2025-09-05
Primary Completion 2026-08-05 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-28